For the quarter ending 2026-03-31, ANAB has $329,684K in assets. $248,469K in cash and cash equivalents.
| Balance Sheets | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Cash and cash equivalents | 248,469 | 238,196 | 109,833 | 44,298 |
| Receivables from collaborative partners | 25,747 | 33,850 | 75,685 | 21,418 |
| Short-term investments | 37,986 | 73,442 | 139,123 | 221,412 |
| Prepaid expenses and other current assets | 3,907 | 4,762 | 6,009 | 4,778 |
| Total current assets | 316,109 | 350,250 | 330,650 | 291,906 |
| Property and equipment, gross | 8,549 | 8,509 | - | - |
| Less accumulated depreciation and amortization | 7,269 | 7,139 | - | - |
| Property and equipment, net | 1,280 | 1,370 | 1,500 | 1,628 |
| Operating lease right-of-use assets | 12,039 | 12,519 | 12,994 | 13,464 |
| Long-term investments | - | 0 | 7,698 | 27,996 |
| Other long-term assets | 256 | 256 | 256 | 256 |
| Total assets | 329,684 | 364,395 | 353,098 | 335,250 |
| Accounts payable | 7,517 | 3,871 | 2,893 | 3,329 |
| Accrued expenses | 32,065 | 32,674 | 33,171 | 30,197 |
| Current portion of operating lease liability | 2,120 | 2,080 | 2,040 | 2,001 |
| Total current liabilities | 41,702 | 38,625 | 38,104 | 35,527 |
| Liability related to sale of future royalties | 263,742 | 276,528 | 331,844 | 331,361 |
| Operating lease liability, net of current portion | 11,493 | 12,032 | 12,566 | 13,095 |
| Common stock, 0.001 par value, 500,000 shares authorized, 29,031 shares and 28,019 shares issued and outstanding at march 31, 2026 and december 31, 2025, respectively | 29 | 28 | 28 | 28 |
| Additional paid in capital | 838,307 | 809,765 | 792,682 | 792,531 |
| Accumulated other comprehensive loss | -146 | -24 | 47 | -6 |
| Accumulated deficit | -825,443 | -772,559 | -822,173 | -837,286 |
| Total stockholders equity | 12,747 | 37,210 | -29,416 | -44,733 |
| Total liabilities and stockholders equity | 329,684 | 364,395 | 353,098 | 335,250 |
ANAPTYSBIO, INC (ANAB)
ANAPTYSBIO, INC (ANAB)